Adam S Kittai

16PUBLICATIONS
128CO-AUTHORS
Molecular targetsPredictive and prognostic markersOncology and carcinogenesis not elsewhere classifiedSolid tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jul 14, 2026
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.

|Apr 29, 2026
Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.

|Nov 05, 2025
PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor-Resistant Chronic Lymphocytic Leukemia.

Britten K Gordon, Elizabeth M Muhowski, Jyotsana Singh

|Feb 20, 2025
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL.

Adam S Kittai, Ying Huang, Sarah Miller

|Dec 23, 2024
Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma.

Swetha Kambhampati Thiruvengadam, Reid Merryman, Yan Wang

|Nov 07, 2024
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma.

Rossana Di Staso, Beatrice Casadei, Frederick L Locke

Pageof 3

Frequent Collaborators

10 joint publications

Jennifer Woyach

4 joint publications

Kerry A Rogers

2 joint publications

John C Byrd

2 joint publications

Mazyar Shadman